- Home
- ENVB vs RNAZ Comparison
ENVB vs RNAZ Comparison
Compare ENVB & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- RNAZ
- Stock Information
- Founded
- ENVB 1994
- RNAZ 2016
- Country
- ENVB United States
- RNAZ United States
- Employees
- ENVB N/A
- RNAZ N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- RNAZ Health Care
- Exchange
- ENVB Nasdaq
- RNAZ Nasdaq
- Market Cap
- ENVB 4.2M
- RNAZ 4.9M
- IPO Year
- ENVB N/A
- RNAZ 2021
- Fundamental
- Price
- ENVB $0.33
- RNAZ $3.84
- Analyst Decision
- ENVB Strong Buy
- RNAZ Strong Buy
- Analyst Count
- ENVB 1
- RNAZ 1
- Target Price
- ENVB $10.00
- RNAZ $20.00
- AVG Volume (30 Days)
- ENVB 156.7K
- RNAZ 69.9K
- Earning Date
- ENVB 11-14-2024
- RNAZ 11-14-2024
- Dividend Yield
- ENVB N/A
- RNAZ N/A
- EPS Growth
- ENVB N/A
- RNAZ N/A
- EPS
- ENVB N/A
- RNAZ N/A
- Revenue
- ENVB N/A
- RNAZ N/A
- Revenue This Year
- ENVB N/A
- RNAZ N/A
- Revenue Next Year
- ENVB N/A
- RNAZ $233.33
- P/E Ratio
- ENVB N/A
- RNAZ N/A
- Revenue Growth
- ENVB N/A
- RNAZ N/A
- 52 Week Low
- ENVB $0.30
- RNAZ $3.21
- 52 Week High
- ENVB $2.92
- RNAZ $264.00
- Technical
- Relative Strength Index (RSI)
- ENVB 40.19
- RNAZ 23.15
- Support Level
- ENVB $0.34
- RNAZ $6.63
- Resistance Level
- ENVB $0.37
- RNAZ $8.46
- Average True Range (ATR)
- ENVB 0.03
- RNAZ 1.04
- MACD
- ENVB 0.01
- RNAZ -0.25
- Stochastic Oscillator
- ENVB 53.66
- RNAZ 1.65
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.